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Abstract
Medullary  thyroid  carcinoma  (MTC)  is  a  neuroendocrine  tumor  (NET),  which
originates  in  neural  crest-derived  calcitonin-producing  C-cells.  It  occurs  either
sporadically or as a result of a germline mutation in the RET proto-oncogene, as in
multiple endocrine neoplasia (MEN) syndrome type 2A including its variant familial
MTC (FMTC) and type 2B. Currently, the only curative treatment for MTC is surgery,
accompanied by lymph node dissection. However, the outcome is largely dependent
on  disease  staging,  with  lymph  node  and  distant  metastases  often  identified  at
diagnosis, particularly in sporadic forms. Furthermore, the presence of cervical lymph
node invasion at surgery predicts residual disease. The development of new treat‐
ments is strongly motivated by: (a) the low surgical cure rate when cervical lymph node
metastases are present at the time of initial surgery, with 90% of patients having residual
disease, (b) the high prevalence of distant metastases at initial diagnosis (lungs, bones
and liver) and (c) the poor outcome in patients receiving cytotoxic chemotherapeutic
agents.  Herein,  we  focus  on  current  nonsurgical  options  and  perspectives  in  the
treatment  of  MTC  with  emphasis  on  last  year’s  FDA-approved  tyrosine  kinase
inhibitors (TKIs) and other systemic therapies that need to be considered in the setting
of advanced disease.
Keywords: thyroid, medullary thyroid carcinoma, therapy, tyrosine kinase inhibitors,
everolimus, somatostatin analogues
1. Introduction
Medullary thyroid carcinoma (MTC) accounts for 1–5% of all thyroid cancers worldwide, with
an apparently descending slope in the prevalence of MTC, at least in the USA, which rather can
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be explained by the marked increase in the relative incidence of papillary thyroid carcinoma
over the past decades [1]. As many as 25–30% of cases harbor a germline mutation in the RET
proto-oncogene and present as a hereditary syndrome, as in multiple endocrine neoplasia (MEN)
syndrome types 2A and 2B [2]. MEN2A, which accounts for 95% of all MEN2 cases, presents
with four variants: classical MEN2A, MEN2A with cutaneous lichen amyloidosis (CLA), MEN2A
with Hirschsprung’s disease (HD) and familial MTC (FMTC, i.e. individuals or families with
RET germline mutations and MTC but without pheochromocytoma or primary hyperpara‐
thyroidism) [1]. Alternatively, MTC develops as a sporadic form, with a peak of incidence
between the 4th and 6th decades of life [3].
A feature of medullary cancer is represented by a variety of hormones or biogenic amines as
secretory products of MTC cells including calcitonin and carcinoembryonic antigen (CEA;
Figure 1) in addition to chromogranin A (CgA), serotonin, neurotensin, adrenocorticotrophic
hormone (ACTH), B-melanocyte stimulating hormone (MSHB) or somatostatin. Of note,
specifically calcitonin and CEA (unspecific) are validated as sensitive tumor markers for the
diagnosis and post-therapeutic follow-up of the disease, and their preoperative serum
concentrations are directly related to the C-cell mass [4].
Figure 1. Microscopy of bifocal, bilobar MTC on a thyroidectomy piece in a c.1901G>T codon 634 mutation carrier. (a)
H–E 40×; (b) IHC anti-calcitonin 20×; (c) IHC anti-CEA 20×; and (d) IHC anti-TTF 20×. Adapted from Sovrea et al. [5],
with permission from the publisher. H–E, haematoxylin–eosin; IHC, immunohistochemistry; CEA, carcinoembryonic
antigen; TTF-1, thyroid transcription factor-1.
Early diagnosis of MTC still represents a challenge in clinical practice. About 70% of patients
with medullary cancer who present with a palpable thyroid nodule have cervical metastases
at initial evaluation; on top of that, 10% have distant metastases [6]. While sporadic forms more
Thyroid Cancer - Advances in Diagnosis and Therapy194
often present as a solitary thyroid mass, hereditary syndromes are frequently multicentric and
bilateral (Figure 1).
On neck ultrasonography, the tumor is typically located in the upper or central parts of the
thyroid lobes in correlation with the distribution of C-cells (Figure 2). The exhibition of
ultrasonographic features of malignancy including hypoechogenicity, irregular margins and
intranodular calcifications correlates with tumor aggressiveness and a poor outcome. On the
contrary, specific ultrasonographic appearance is lacking, and up to one-third of MTC may
appear as non-suspicious on neck ultrasonography [7]. Overall, cost analysis suggests cost-
effectiveness of calcitonin screening in patients with nodular goiter [8] and, subsequently,
deepening investigations in patients with basal serum calcitonin levels at screening >20 pg/mL
is recommended. Use of high-sensitivity immunoassays for measurements of calcitonin or,
alternatively, a calcium-stimulation test, is indicated in patients with mildly elevated calcitonin
levels.
Figure 2. Grey-scale image of medullary thyroid carcinoma (MTC). (A) Cranio-caudal section and (B) transversal sec‐
tion.
Contrast-enhanced computer tomography (CT) scanning of the neck and chest (lymph nodes,
lung metastases), contrast-enhanced CT or magnetic resonance imaging (MRI) of the liver,
axial MRI and bone scintigraphy should be considered in patients with confirmed, extensive
neck disease and signs of regional or distant metastases and in the presence of a serum
calcitonin level above 400–500 pg/mL, as these patients almost always harbor systemic disease
[9, 10]. Sensitivity of FDG-PET/CT or F-DOPA-PET/CT in detecting MTC metastases appears
to be lower compared to other imaging investigations [1].
Recently revised American Thyroid Association (ATA) Guidelines for the management of
medullary thyroid carcinoma suggest that fine needle aspiration biopsy (FNAB) should be
performed in all thyroid nodules that are 1 cm or greater in size [1]. According to a meta-
analysis, FNAB has been shown to have an accuracy of less than 50% in diagnosing MTC in
affected subjects; however, diagnostic accuracy of FNAB analysis is significantly improved by
measuring calcitonin levels in the FNA washout fluid [11]. In addition, immunohistochemistry
analysis with positivity for calcitonin ± CEA and CgA and absence of thyroglobulin (Tg)
staining of the FNAB specimen is reassuring [1].
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In advanced disease, markedly increased basal CEA in addition to discordantly lower
calcitonin, or normal or low levels of both CEA and calcitonin (i.e. nonsecretory MTC) suggests
poorly differentiated MTC. Screening for RET mutations is indicated as well, since it has been
shown that up to 7% of patients with apparently sporadic MTC have hereditary disease [12].
There is evidence of central and lateral compartment lymph node metastases in 14 and 11% of
patients with stage T1 tumor, whereas an incidence of 86% and 93%, respectively, has been
reported in stage T4 [13]. Ten-year survival rates of 100% for stage I disease, 93% for stage II,
71% for stage III and 21% for stage IV MTC have been reported [14].
2. Conventional treatment strategies of medullary thyroid carcinoma
2.1. Surgery
Thyroidectomy is the only curative treatment for both sporadic and hereditary MTC, accom‐
panied by dissection of cervical lymph node compartments. Patients who carry RET mutations
should undergo prophylactic thyroidectomy upon genetic diagnosis, even during childhood
but at different ages depending on the risk associated with the specific RET mutation. Radical
surgery is rarely possible in advanced regional/distant disease and rather preservation of
swallowing, speech and parathyroid function should be attempted [1].
The outcome of surgery is largely dependent on disease staging, with 10-year survival rate of
96% in localized disease but rapidly decreasing to a median survival rate of 3 years after
evidence of distant metastases. Normalization of calcitonin (<10 pg/mL) and CEA is only seen
in 40% of cases, and approximately 9% of patients who have achieved biochemical cure will
later develop recurrent disease [14]. A primary tumor larger than 1 cm diameter in the presence
of high preoperative basal calcitonin levels (>20 pg/mL) and CEA concentrations (>10 pg/mL)
predicts lymph node metastases in both central and ipsilateral neck compartments [15].
Following surgery, patients undergo levothyroxine replacement therapy in order to maintain
serum thyroid stimulating hormone (TSH) levels in the normal range. In patients with
unilateral lobectomy in whom MTC was histologically confirmed, completion thyroidectomy
is indicated in the presence of elevated postoperative calcitonin or imaging studies indicating
residual disease, or patients in whom a positive RET germline mutation was confirmed. In
residual MTC, the calcitonin doubling time bears significant prognostic value. Patients whose
calcitonin doubling time is 1 year or less have 10-year survival rates of 18%, whereas those
with calcitonin doubling time longer than 1 year have a 95% survival rate [16].
According to 2015 ATA guidelines, postoperative care is based upon the dynamics of tumor
markers and ultrasonographic findings. Therefore, serum levels of calcitonin and CEA should
be measured 3 months after surgery, and if undetectable or within the normal range, every 6–
12 months, then yearly. If calcitonin levels are high, yet less than 150 pg/mL, and however,
there is no evidence of loco-regional disease on ultrasonography, measurement of serum
tumor markers and thyroid ultrasonography every 6 months are strongly recommended.
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Should calcitonin levels exceed 150 pg/mL postoperatively, patients should undergo extensive
imaging studies to detect persistent disease and/or metastases [1].
2.2. External beam radiation therapy
Adjunctive external beam radiation of the neck or mediastinum could be considered after
surgery in MTC patients with high risk for local recurrence (i.e. residual tumor, extra-thyroidal
extension, extensive lymph node metastases) or airway obstruction, when repeat surgery is
not possible. External beam radiation therapy has been used as a therapeutic method to control
local tumor growth in patients with advanced loco-regional disease and implies postoperative
delivery of 60–66 Gy over 6 weeks to the thyroid bed, although higher doses may be needed
in the presence of important residual disease [1]. Although external radiation therapy posi‐
tively affects the quality of life [17, 18], it appears not to significantly alter the overall survival
rate in patients with lymph node metastases as shown by Martinez et al. [19]. External radiation
beam therapy adverse effects include skin erythema, laryngeal edema, mucositis and esoph‐
agitis in the early phase. Later on, osteonecrosis, arterial injury, brain or cranial nerve injury
are encountered.
Additional indications of external beam radiation therapy are painful bone metastasis, for
palliation, or for the prevention of other bone-related complications such as fractures or spinal
cord compression. Bone metastases may also benefit from high-dose anti-resorptive therapy
(intravenous bisphosphonates or RANK-ligand inhibitor human monoclonal antibody).
2.3. Radioactive iodine
Previous studies certified lack of significant effect of radioactive iodine treatment in patients
with MTC, as C-cells do not concentrate iodine. It was hypothesized that radioiodine, con‐
centrated by follicular cells, might induce C-cell apoptosis through a bystander effect, how‐
ever, not confirmed. In 2013, a controlled multicentre study compared the outcome of 232
patients with local or loco-regional MTC treated only by surgery to 61 matched patients that
were also treated with RAI and found no difference in terms of disease-free or disease-specific
survival [20]. On the contrary, radioactive iodine therapy should be considered in patients
with MTC if the primary tumors or metastases contain MTC mixed with papillary or follicular
thyroid carcinoma [1].
2.4. Conventional chemotherapy
Indication of cytotoxic chemotherapy is limited to advanced MTC, when disease control cannot
be achieved with other treatments, however, with limited efficacy. Single agent or combination
chemotherapeutic regimens generally show low response rates (15–20%), and of short duration
(a few months), whereas large clinical trials demonstrating survival benefits are lacking.
According to the National Comprehensive Cancer Network (NCCN), dacarbazine is the
drug of choice in patients with disseminated, symptomatic disease [21], in combination to
5-fluorouracil (5FU). Apart from that, dacarbazine has been combined with other cytotoxic
agents such as cyclophosphamide, vincristine, streptozotocin and epirubicin, with modest
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results. Few studies and case reports have focused on the use of capecitabine, a 5FU pro-
drug that preferentially accumulated in tumors rather than in plasma to inhibit tumor cell
proliferation [22], with apparently encouraging effects in stabilizing MTC patients with
advanced disease. In a small phase I study, the combination of imatinib with capecitabine
and dacarbazine failed to induce an objective response in MTC but four of five patients
subjected to the therapeutic regimen maintained stable disease [23]. A combination of ca‐
pecitabine with temozolomide appears to improve metastatic MTC [24], but experience is
limited to isolated case reports.
Alternatively, combination treatment regimens with doxorubicin and another agent (e.g.
cisplatin) may be used [1].
3. Molecular targeted therapies in medullary thyroid carcinoma
Systemic therapy is solely reserved for metastatic, unresectable, unstable MTC (i.e. calcitonin
doubling time below 2 years) [1] or symptomatic tumor progression that cannot be managed
by localized organ therapy [21]. Severe diarrhea that does not respond to symptomatic
medication might need systemic therapy.
In contrast to classic cytotoxic chemotherapeutic agents that show weak specificity in discrim‐
inating between normal and tumor cells, the use of targeted molecular therapies is advanta‐
geous by providing a more narrow and specific therapeutic window and less toxicity. The
broader spectrum of targeted therapies in neoplastic disease includes: (a) tyrosine kinases
inhibitors (TKIs), (b) anti-sense inhibitors of growth factor receptors and (c) monoclonal
antibodies. Tyrosine kinases play key roles in the modulation of growth factors signaling. For
instance, RAS activation depends on epidermal growth factor receptor (EGFR), and somatic
RAS mutations have been described in patients with MTC in the absence of RET mutations
[25]. Apart from the activation by growth factors, protein kinase activation by germline or
somatic mutations is a mechanism commonly described in tumor genesis. In fact, about 50%
of the patients with sporadic MTC have somatic mutations of RET proto-oncogene, besides
patients with MEN2 syndrome, of whom 98% express germline RET mutations [26]. In
addition, MTC cells often overexpress vascular endothelial growth factor receptors (VEGFRs).
TKI intervenes by blocking the ATP site of the tyrosine kinase receptors to prevent tyrosine
kinase activation. They inhibit thyroid tumor cell proliferation, migration and survival and
angiogenesis.
3.1. Tyrosine kinase inhibitors
Of all TKIs, the Food and Drug Administration (FDA) recently approved vandetanib and
cabozantinib as first-line agents for the treatment of symptomatic or progressive MTC in
patients with unresectable or metastatic disease. Both American Thyroid Association (ATA)
and National Comprehensive Cancer Network guidelines (NCCN) specifically address the
two drugs to patients with advanced MTC [1, 21]. Vandetanib and cabozantinib are multi-
kinase inhibitors, with vandetanib targeting several cell-signaling pathways involved in the
Thyroid Cancer - Advances in Diagnosis and Therapy198
pathogenesis of MTC, including receptor tyrosine kinase RET, VEGFR-2 and -3 and EGFR
and cabozantinib blocking RET, VEGFR-2 and c-MET [27], without simultaneously over-ex‐
pressing any of the factors leading to the inhibition of angiogenesis. However, neither drug
shows a clear correlation between RET mutational status and efficacy.
3.1.1. Vandetanib
In a trial with a phase II design on 30 adult patients with advanced MTC, of whom 70% had
hereditary forms, objective partial response was obtained in 20% of patients while in 53%
disease remained stable for 24 weeks during vandetanib 300 mg daily [28]. Vandetanib 100
mg/m2/d was confirmed as a relatively well-tolerated and effective treatment in children (5–
18 years) positive for M918T RET germline mutations [29].
In a phase III, randomized, double-blind, placebo-controlled trial (ZETA trial) of 331 patients
with unresectable locally advanced (5%) or metastatic (95%) MTC, vandetanib 300 mg once
daily resulted in significant prolongation of median progression-free survival to a predicted
30.5 months in the vandetanib group in comparison to 19.3 months in the placebo group [30].
The overall response rate to vandetanib was 44% and was noticed in both patients positive for
RET mutations and those without a RET mutation. At the end of the study, 35% of study
subjects required dose reductions, and 12% discontinued therapy due to toxicity. A fatal
adverse effect was reported in 2.5% of patients.
Tumor markers calcitonin and CEA may fluctuate in patients undergoing therapy with
vandetanib, often with an initial drop of the marker levels. A rise in calcitonin levels ≥40%
between two follow-ups during the treatment for MTC appears to predict tumor progression
early [31].
Vandetanib carries a black box warning for prolongation of the QT interval, torsades de
pointes and sudden death. During treatment, medications that may prolong the QT interval
must be avoided, and patients must undergo regular EKGs and serum electrolyte control.
Patients with a history of long QT syndrome, baseline rate-corrected QT >450 ms, or uncor‐
rectable electrolyte abnormalities should be excluded from treatment [32]. Other common
adverse effects of vandetanib include diarrhea, nausea, fatigue and abdominal pain. In
addition, hypertension, headache, acne and rash were reported. Hypocalcaemia, hepatocyto‐
lisis, hypoglycemia, hypertriglyceridemia [33], hypothyroidism and increased creatinine are
common laboratory findings. In patients who cannot tolerate recommended dose, there is
preliminary evidence that low-dose vandetanib is also efficient [34]; however, further studies
are warranted.
Drug resistance to vandetanib has been described. Rare RET mutations V804M and V804L
confer resistance to vandetanib as do RAS mutations, identified in 60–80% of RET-negative
sporadic MTC cases. Sorafenib could be effective in these particular situations [26]. In vitro
testing of tumor cell sensitivity to TKI, even in cell cultures prepared from fine needle
aspiration specimens [35], has been shown to have a 60% positive predictive value of clinical
response in the same patient and a 90% negative predictive value.
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3.1.2. Cabozantinib
Cabozantinib approval was obtained following a phase III randomized, double-blind, placebo-
controlled trial that enrolled 330 patients with progressive, metastatic or locally advanced
MTC, in whom median progression-free survival increased significantly from 4.0 months in
the placebo group to 11.2 months in the cabozantinib group [36]. The overall response rate was
28%. More than half of patients developed adverse effects such as diarrhea, stomatitis and
palmo-plantar erythrodysesthesia. Other adverse effects were similar to those observed for
vandetanib (nausea, abdominal pain, fatigue, hypertension). Hepatocytolysis, hyperbilirubi‐
nemia, neutropenia and thrombocytopenia were also encountered. Rare but severe adverse
effects were gastrointestinal perforation and fistula and hemorrhage, also included on the
black box warning. Thromboembolic events, osteonecrosis of the jaw and reversible posterior
leukoencephalopathy syndrome were also mentioned. A total of 16% of patients discontinued
treatment due to toxicity and 79% required dose reductions; 6% of patients experienced fatal
adverse reactions. In view of major adverse effects, patients with a history of diverticulitis,
chronic inflammatory gastrointestinal disease, active peptic ulcer, radiation to the neck or
mediastinum as well as tumor invasion characteristics that may predispose to fistulas and
hemorrhage need to be identified. A systematic review and meta-analysis on small-molecule
TKI in patients with thyroid cancer published by Klein Hesselink et al. concluded that
vandetanib and cabozantinib resulted in objective responses in 40% (95% CI 34–46%) and 27%
(95% CI 22–32%) of patients with advanced MTC [37]. In clinical practice, response to cabo‐
zantinib was documented following a failed vandetanib treatment [38].
In conclusion, TKI vandetanib and cabozantinib have demonstrated important rates of disease
control at the cost of significant drug toxicity. Still, TKIs are less toxic when compared to
conventional cytotoxic agents. Further studies assessing the impact on overall survival for both
agents are warranted, as previous studies failed to demonstrate prolonged survival. Head-to-
head studies comparing the efficacy of the two drugs in patients with advanced MTC are
lacking, therefore selection of one treatment over the other needs evaluation of potential risks
and benefits for each patient. Factors that might influence the choice of TKI in patients with
MTC are related to patient and drug characteristics, laboratory and cardiologic assessments,
past medical history and concomitant medication. Cabozantinib is favored in patients with or
at risk for long QT syndrome (baseline QTcF interval >450 ms), patients with uncorrected
baseline dyselectrolitemia (hypocalcemia, hypomagnesemia or hypokalemia), patients unable
or unwilling to protect from sun exposure or in the case of rapid disease progression. On the
contrary, vandetanib should be firstly considered in patients with gastrointestinal comorbid‐
ities or tumors invading the trachea, esophagus, or major blood vessels because of the risk of
perforation or fistula [39]. Concomitant use of a CYP3A4 inhibitor drug may increase the
plasma concentration of cabozantinib, resulting in toxicity, whereas use of a CYP3A4 inducer
may decrease the efficacy of vandetanib [32, 39]. Vandetanib may cause weight gain, whereas
cabozantinib should be avoided in patients with low body mass index.
Several case reports indicated that both vandetanib and cabozatinib might successfully control
ectopic Cushing’s syndrome associated to MTC [40].
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3.1.3. Sorafenib
Sorafenib, currently approved for the treatment of renal cell and hepatocellular carcinomas,
constitutes first-line indication in advanced radioiodine-refractory differentiated thyroid
carcinomas (DTCs). Reviewing retrospectively 13 patients with advanced MTC treated with
sorafenib 400 mg twice daily, de Castroneves et al. observed stable disease in 10 (83.3%)
patients [41]. A systematic review of sorafenib in metastatic thyroid cancer (both DTC and
MTC) noticed an overall partial response rate of 22% for MTC patients, with only 6.5% having
progressive disease, which suggests a reasonable clinical benefit [42]. However, treatment with
sorafenib is associated with considerable toxicity, leading to highest rates of dose reduction or
discontinuation [37].
3.1.4. Sunitinib
Sunitinib, available for gastrointestinal stromal tumors (GIST), renal cell carcinomas and
pancreatic neuroendocrine tumors (pNET), was investigated in a small phase II study, and a
response was objectivized in three of six (50%) patients with metastatic MTC and radiologically
evaluable lesions, but more than 10% of treated patients experienced grade 3 or higher toxicities
[43]. In a recent meta-analysis, encouraging results were obtained with sunitinib, with a clinical
benefit in 43% of patients (n = 36) with advanced MTC [37].
3.1.5. Axitinib, motesanib, lenvatinib, ponatinib
Other kinase inhibitors have been investigated, with small trials showing variable results.
Axitinib is an oral TKI that inhibits VEGFRs, c-KIT and PDGFR-β, approved for the treatment
of renal carcinoma. A multicenter, open-label, phase II study examined the efficacy of axitinib
in 60 patients with advanced or metastatic thyroid carcinoma of all histological subtypes [44].
Overall, 18% of patients with MTC presented partial response, with median progression-free
survival of 18.1 months. Axitinib was relatively well tolerated, with the most common adverse
event being hypertension. Another multicenter phase II study aimed at investigating the
efficacy and tolerability of motesanib in 91 patients with locally advanced or metastatic,
progressive or symptomatic MTC. Only two patients (2%) experienced a partial response, and
stable disease was achieved in 74 patients (81%), lasting for 24 weeks or longer in 44 (48%) [45].
Ponatinib, a newer multi-kinase inhibitor used in the treatment of chronic myeloid leukemia
and acute lymphoblastic leukemia, showed promising results in early trials, but it carries a
black box warning due to a high rate of arterial thrombotic events.
A multi-kinase inhibitor targeting VEGFR-1-3, FGFR-1-4, RET, c-KIT and PDGFR-β is
lenvatinib. Moreover, lenvatinib has been shown to be able to inhibit FGFR-1, thus targeting a
pathway involved in resistance to VEGF-pathway inhibitors. In a phase II trial enrolling 59
patients with advanced MTC, an objective response rate was documented in 59%, stable
disease was confirmed in 36% and a median progression-free survival of 13.3 months was
reported [46].
Neither geftinib nor imatinib induced objective responses in patients with advanced, progres‐
sive MTC [37].
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The response of individual cases to TKI could be subjected to influence by the expression of
RET or RAS mutations in the primary tumor, and Mancikova et al. found that in contrast to
RET-positive tumors, RAS-positive tumors express neither PDGFR-β nor MET and poorly
express VEGFR-3 [47], thus suggesting that intracellular targets of TKI are expressed according
to the presence of RAS mutations, a potentially useful information in the selection of patients
receiving treatment with TKI.
Summary
In summary, TKI, specifically vandetanib and cabozantinib, demonstrated a response rate
of 27–44% in randomized trials and meta-analyses, to support first-line therapeutic indica‐
tion in the management of symptomatic or progressive MTC in patients with non-resecta‐
ble or metastatic disease. Nevertheless, dose-dependent toxicity of these drugs is
considerable, including gastrointestinal perforations, fistulas and hemorrhage for cabozanti‐
nib and prolongation of the QT interval, torsades de points and sudden death for vandetanib.
Liver failure, pulmonary arterial hypertension and development of secondary malignancies
have been reported. Apparently, regression or stabilization of skeletal metastases related to
advanced MTC is weakly influenced by TKI, although cabozantinib may exert some activity
against certain types of bone lesions [43]. Overall, the quality of life is markedly affected by
TKI with adverse effects reported by 30–60% of patients and serious adverse events occur‐
ring in 2% of cases [48]. The evidence for sorafenib and sunitinib in MTC is not as strong,
but small studies have demonstrated their efficacy. Other kinase inhibitors have shown var‐
iable results.
3.2. Mammalian target of rapamycin (mTOR) inhibitors
There is solid evidence that the PI3K/Akt pathway is extensively involved in cell growth,
proliferation and survival of all types of thyroid tumors. The mTOR kinase is a component of
the PI3K signaling pathway, and AKT/mTOR activation is demonstrated in DTC and MTC
with AKT/mTOR immunostaining present in more than 50% of medullary carcinoma cells [48].
In vitro experiments showed oncogenic RET may regulate mTOR activity in patients with MTC.
Moreover, low-concentration RET and mTOR inhibitors administered as a combination, to
concomitantly target RET and mTOR, acted cooperatively in cell culture experiments [49].
Prospective phase II trials with everolimus, an mTOR inhibitor, in patients with advanced
MTC reported promising results. In one small-sized study, stable disease was obtained in five
of seven (71%) patients [50]. The most frequent side effects in everolimus trials were fatigue,
mucositis and hypertriglyceridemia, but overall the drug was well tolerated. Further investi‐
gations are warranted to evaluate the efficacy of everolimus as monotherapy or combined with
other targeted agents in patients with advanced MTCs. Table 1 depicts relevant randomized
and non-randomized studies on treatment with TKI and mTOR inhibitors in patients with
MTC.
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Author Study design Drug regimen Objective
partial
response
(PR)%
Stable
disease
(SD)%
Common adverse effects
Wells et al., 2010
[28]
Open-label, phase II
trial
Vandetanib 300
mg/day
20 53 Diarrhea, rash, fatigue,
nausea
Robinson et al.,
2010 [34]
Open-label, single-arm
trial
Vandetanib 100
mg/day
16 53 Diarrhea, fatigue, rash,
constipation, anorexia, back
pain, nausea,
photosensitivity
Wells et al., 2012
[30]
Randomized, double-
blind, placebo-
controlled phase
III trial
Vandetanib 300
mg/day
45 87 Diarrhea, rash, nausea,
hypertension, headache
Chougnet et al.,
2015 [51]
Retrospective cohort Vandetanib 300
mg/day
20 55 Skin toxicity, diarrhea,
asthenia
Kurzrock et al.,
2011 [38]
Open-label, phase I
dose-escalation study
Cabozantinib
(maximum-
tolerated dose =
175 mg/day)
29 41 Diarrhea, fatigue, decreased
appetite, nausea, palmar-
plantar erythrodysesthesia
(PPE), rash, hepatocytolysis
Elisei et al., 2013
[36]
Randomized, double-
blind, placebo-
controlled phase
III trial
Cabozantinib 140
mg/day
28 47.3
(progression-
free at 1 year)
Diarrhea, decreased weight
and appetite, PPE, nausea,
fatigue
Capdevila et al.,
2012 [52]
Retrospective
longitudinal study
Sorafenib 2 × 400
mg/day
47 40 PPE, diarrhea, rash,
asthenia, anorexia,
stomatitis, hypertension,
abdominal pain
de Castroneves
et al., 2016 [41]
Retrospective,
longitudinal study
Sorafenib 2 × 400
mg/day
0 83.3 PPE, weight loss, fatigue
De Souza et al.,
2010 [53]
Nonrandomized,
open-label, phase II
study
Sunitinib 50 mg/
day, 4/2 week
schedule
35 57 Fatigue, lymphopenia,
neutropenia, nausea,
diarrhea, mucositis, PPE
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Author Study design Drug regimen Objective
partial
response
(PR)%
Stable
disease
(SD)%
Common adverse effects
Carr et al., 2010
[19]
Non-randomized,
open-label, phase II
study
Sunitinib 37.5
mg/day
50 71 Fatigue, diarrhea, PPE,
neutropenia
Lim et al., 2013
[54]
Non-randomized,
open-label, single-arm
phase II study
Everolimus 10
mg/day
0 100 Mucositis, anorexia,
hepatocytolysis
Schneider et al.,
2015 [50]
Non-randomized,
open-label, single arm
phase II study
Everolimus 10
mg/day
0 71 Mucositis, fatigue,
hypertriglyceridemia
Table 1. Randomized and non-randomized studies on tyrosine kinase inhibitors (TKIs) and mammalian target of
rapamycin (mTOR) inhibitors in advanced medullary thyroid carcinoma (MTC).
3.3. Somatostatin analogues (SSA)
Medullary thyroid cancers are neuroendocrine tumor (NET) that expresses cell surface
somatostatin receptors (SSTRs) in less than 40% of cases; however, these cases may respond
favorably to SSA treatment. Octreotide and lanreotide, the currently available SSA with high
affinity for SSTR2 and SSTR5, may be helpful in controlling symptoms in advanced MTC, but
they do not appear to significantly affect tumor burden or disease course. Indeed, SSA should
be considered in case of flushing and diarrhea, if other drugs are ineffective [55].
3.4. Peptide receptor radiation therapy (PRRT)
There is limited experience with PRRT targeting SSTR2 and cholecystokinin (CCK) receptors
A and B, which are expressed by medullary carcinomas, in patients with advanced, metastatic
MTC [55]. A phase II trial evaluating systemic 90Y-DOTATOC treatment in selected patients
with stage IV MTC showed encouraging response and survival rates: 29% of the 31 study
patients experienced reduction of serum calcitonin levels and had a significantly longer
median survival from onset of treatment in comparison to non-responders (i.e. 74.5 months
vs. 10.8 months); however, 13% of patients developed serious hematological toxicity, and 23%
developed nephrotoxicity [56].
One study evaluated CCK-B/gastrin receptor-based PPRT and included eight patients with
advanced MTC to whom the radioligand 90Y-DTPT-D-Glu-minigastrin was administered. Of
all, two patients developed partial remission and four had stable disease; severe adverse events
were encountered, with one patient developing chronic myelogenous leukemia and another
patient developing chronic renal failure [57]. Treatment with 177Lu-DOTATATE reached
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similar results with three of nine patients having partial response and other three presenting
stable disease [58]. Current guidelines suggest that PRRT should be taken into account in well-
selected cases [1].
3.5. Experimental therapies
A number of other treatments are in the early phases of development. Pre-targeted radio
immunotherapy with bi-specific monoclonal antibody (BsMAb) and 131I-labeled bivalent hapten
has shown positive results in advanced, progressive MTC, but prospective, randomized trials
comparing this therapy to other therapies or placebo are needed [1].
Vaccination with autologous dendritic cells pulsed with MTC-specific antigens (CEA or calcitonin)
has been attempted, inducing specific immunoreactivity and leading to a clinical response in
three of seven patients in one small study [59].
Combination therapy of a TKI (e.g. vandetanib) and a protease inhibitor (bortezomib) appears
to induce synergistic effects in cell culture experiments [60], being under evaluation in human
trials.
Treatment with plitidepsin, an antibiotic that can induce tumor apoptosis, has been used in 16
subjects with unresectable MTC in a phase II trial, with modest clinical benefits and manage‐
able toxicity [61].
The HIV-protease inhibitor nelfinavir has been shown to decrease RET expression and induce
apoptosis in medullary thyroid cancer cells, but clinical studies are needed to prove its efficacy
in treating MTC [62].
Metformin is an anti-diabetic drug that seems to inhibit cancer cell viability through the
inhibition of mTOR, an effect that was also observed in MTC cell lines [63]. Metformin is under
testing in clinical trials in combination with other agents.
AZD 1480, a JAK 1,2 inhibitor, was shown to block proliferation and tumor growth of RET-
activated thyroid cancer cells, supporting its use in advanced MCT; however, further research
is needed [64].
Enzastaurin is a protein kinase C inhibitor that has been shown to produce tumor cell apoptosis
and suppress tumor-induced angiogenesis. Its value in the treatment of advanced MTC is
under investigation.
Epigenetic drugs, that target DNA methylation and acetylation, are regarded with increasing
interest. Histone deacetylases regulate gene expression and cell cycle, proliferation and
apoptosis. Histone deacetylase inhibitors have been shown to suppress proliferation of thyroid
cancer cells, but evidence is based on small studies [48]. Combined targeted therapy is also
currently under investigation.
3.6. Treatment of hormonally active metastases
Co-secretion of hormones other than calcitonin can often be observed in medullary carcino‐
ma. The prevalence of diarrhea is related to tumor volume. From a pathogenic viewpoint,
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diarrhea is due to either hypersecretory or increased gastrointestinal motility. Treatment in‐
cludes anti-motility drugs (loperamide, diphenoxylate/atropine, codeine) and, in selected
cases, SSA. When these therapies are insufficient, palliative surgery or chemoembolization
may be helpful.
In cases of ectopic CRH or ACTH syndromes associated with unresectable MTC, steroidogen‐
esis inhibitors and ultimately bilateral adrenalectomy should be considered.
4. Conclusions
The treatment of residual or recurrent medullary thyroid carcinoma (MTC) continues to be a
challenge. Although surgery remains the mainstay of therapy, it can be curative only in the
early stages of the disease. External beam radiotherapy and cytotoxic chemotherapy with
dacarbazine and doxorubicin-based regimens may be useful in select patients, but with little
or no impact on overall survival. In recent years, there has been significant progress in the
treatment of advanced, metastatic MTC. The use of tyrosine kinase inhibitors (TKIs), cabo‐
zantinib and vandetanib, as first-line agents for symptomatic metastatic and progressive MTC
has significantly improved progression-free survival, showing high rates of partial response
and disease stabilization; however, prolonged survival has not been confirmed yet. The search
continues for kinase inhibitors that can be used in patients who are unresponsive or develop
resistance to existing drugs. Ongoing clinical trials evaluate additional agents that might
significantly impact future management of the disease.
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